DeCEDA/Qrius 2022 was a milestone year for India. India walked into 2022 with an infectious wave of Covid-19 impacting lakhs of people, the wave receded a few weeks into the year. As hopes for a post-pandemic recovery surged, war in Ukraine brought in new challenges for the economy. With supply chains disrupted, global sanctions imposed on Russia, prices of fuel and food shot up. Inflation, already on a high from pent-up...

-The Telegraph Alertness among public and preparedness by healthcare institutions is always good, says Organised Medicine Academic Guild’s secretary-general New Delhi: A body of medics has called on fellow doctors and government agencies to acknowledge India’s largely safe status against existing Coronavirus variants and avoid “scaremongering” lest the public disregard caution if and when a “real wolf” arrives. The Organised Medicine Academic Guild (Omag), a body of 15 professional medical associations with a...

-The Telegraph Centre’s vaccine policy advisers earlier this week approved release of intranasal vaccine into the private market New Delhi: Indian vaccine maker Bharat Biotech announced on Tuesday that its intranasal Covid-19 vaccine, approved by the Centre as a booster dose, would be available at private hospitals for Rs 800 plus additional taxes and service charges per dose. People 18 years or older who have taken two doses of Covaxin, Covishield or any...

-Scroll.in An acute shortage of teachers was also noticed in the state, a report prepared by Economist Jean Dreze stated. Fifty-three percent of teachers who were part of a survey have said that most students in primary and upper-primary government schools in Jharkhand had forgotten how to read and write by the time schools reopened in February 2022 after the Coronavirus pandemic. Primary and upper-primary schools were closed in Jharkhand since the onset...

-Hindustan Times On November 15, Boston-based health news website Stat News cited official documents that purported to detail a series of problems in how Bharat Biotech’s Coronavirus vaccine, funded partly by the government, was approved. The Union government and vaccine maker Bharat Biotech on Thursday refuted a report that alleged rules and protocols were bent during the approval process for Covaxin, but the clarifications served to further add to the questions that...